Principal Investigator/Program Director (Last, First, Middle):
Visootsak, Jeannie
OTHER SUPPORT
ACTIVE
1K23HD058043-01A1
NIH/NICHD
02/01/09-02/01/13
9 calendar month
$513,000
Mentored Patient-Oriented Research (POR) Career Development Award
Title: Neurodevelopmental Impact of Congenital Heart Defects in Down Syndrome
Role of Project: Principal Investigator
Novartis Pharmaceuticals
09/01/10-05/31/12
.6 calendar month
$329,927
Title: A randomized, double-blind, placebo-controlled, parallel group study to evaluate AFQ056 in adult patients with
Fragile X Syndrome
Role of Project: Principal Investigator
Novartis Pharmaceuticals
01/15/11-09/01/12
.12 calendar month
$274,329
Title: A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of AFQ056
in adolescent patients with Fragile X Syndrome
Role of Project: Principal Investigator
Novartis Pharmaceuticals
12/01/11-12/01/12
.12 calendar month
$276,162
Title: An open-label study to evaluate the long-term safety, tolerability and efficacy of AFQ056 in adult patients with
Fragile X Syndrome
Role of Project: Principal Investigator
Novartis Pharmaceuticals
02/01/12-02/01/14
.12 calendar month
$451,505
Title: An open-label study to evaluate the long-term safety, tolerability and efficacy of AFQ056 in adolescent patients with
Fragile X Syndrome
Role of Project: Principal Investigator
Seaside Therapeutics
04/27/2011-05/01/2013
.3 calendar month
$115,000
Title: A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209
(Arbaclofen) Administered for the Treatment of Social Withdrawal in Children with Fragile X Syndrome
Role of Project: Principal Investigator
Seaside Therapeutics
04/27/2011-05/01/2013
.3 calendar month
$115,000
Title: A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209
(Arbaclofen) Administered for the Treatment of Social Withdrawal in Adolescents with Fragile X Syndrome
PHS 398 (Rev. 11/07)
Page
Other Support Format Page (continued)
Principal Investigator/Program Director (Last, First, Middle):
Visootsak, Jeannie
Role of Project: Principal Investigator
Seaside Therapeutics
12/01/2011-12/01/2012
.12 calendar month
$260,161
Title: An Open-Label Extension Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of STX209 (Arbaclofen)
in Subjects with Fragile X Syndrome
Role of Project: Principal Investigator
PHS 398 (Rev. 11/07)
Page
Other Support Format Page (continued)